Login to Your Account

Financings Roundup

Aileron $12M Raise to Propel Stapled Peptide into Clinic

By Marie Powers
Staff Writer

Monday, January 14, 2013
Aileron Therapeutics Inc. secured a second tranche of $12 million in its Series D financing, bringing the total round to $42 million and positioning its lead stapled peptide drug, ALRN-5281, to enter the clinic in orphan endocrine disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription